Association between laboratory results on day 8 of onset and the clinical outcome of COVID-19 patients

Abstract

Background: Pneumonia (COVID-19) caused by the novel coronavirus (2019-nCoV) outbreak attracted global attention. However, early prognostic biomarkers on clinical outcomes about COVID-19 patients is not clear by now. Methods: We collected the clinical data of the 85 COVID-19 patients confirmed in the local hospital. The patients' clinical baseline data, serological data, outcome data were retrospectively analyzed. This study aimed to figure out monitoring values for early prediction of clinical outcome. Results: Dynamic monitoring of laboratory examination indicators during hospitalization showed that the second week is a critical time window of disease progression. Beginning on the 8th day, severely reduced lymphocytes accompanied by a severe increase in inflammation indicators and abnormally high fibrinogen occurred in serious patients. Plasma fibrinogen was increased (5.23 vs 3.87 g/L, P < 0.001), and lymphocyte count (0.71 vs 1.42 109/L, P < 0.0001) was significantly reduced. On the 8th day of disease course, when the lymphocyte count was lower than 1.23×109/L, the time of negative conversion of viral nucleic acid was prolonged (P = 0.051), and imaging showed that the chest CT absorption time was prolonged (P < 0.01). When fibrinogen was greater than 4.24, the time to viral nucleic acid negative conversion was prolonged (P < 0.01), and imaging showed that chest CT absorption time was prolonged (P < 0.001).Conclusion: the Lymphocyte count might be related to clinical outcome events. It could act as laboratory indicators of disease severity.